Gilead Sciences Inc logo

GILD - Gilead Sciences Inc News Story

$59.96 -0.8  -1.4%

Last Trade - 26/10/20

Sector
Healthcare
Size
Large Cap
Market Cap £57.72bn
Enterprise Value £61.80bn
Revenue £17.03bn
Position in Universe 129th / 6393

BRIEF-Gilead's Magrolimab Receives FDA Breakthrough Therapy Designation

Tue 15th September, 2020 2:14pm
Sept 15 (Reuters) - Gilead Sciences Inc  GILD.O :
    * GILEAD’S MAGROLIMAB, AN INVESTIGATIONAL ANTI-CD47
MONOCLONAL
ANTIBODY, RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR
TREATMENT OF MYELODYSPLASTIC SYNDROME

Source text for Eikon:  ID:nBw7DFQf3a 
Further company coverage:  GILD.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.